Details of Drug

Drug General Information (ID: D1179)
Drug Name	Omeprazole
Drug Type	Small molecule
Drug Synonymous	Losec (TN) Click to Show/Hide
Disease Class	DA22: Gastro-oesophageal reflux disease
Therapeutic Class	Antiulcer Agents
Structure
Structure	3D Structure		2D Structure
Formula	C17H19N3O3S
InChI	1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
InChIKey	SUBDBMMJDZJVOS-UHFFFAOYSA-N
Canonical SMILES	CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC
External Link
	Pubchem ID	4594
	CAS Number	73590-58-6
	CHEBI ID	77260
	TTD ID	D01XNB
	INTEDE ID	DR1196
	VARIDT ID	DR00387

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM002 Affected cellular transport AM004 Affected intra/extra-hepatic metabolism AM005 Affected excretion pathways AM006 Pharmacodynamic additive effects BM005 Altered gastric pH BM009 Altered absorption (Unspecific) BM010 Transporter inhibition BM011 Transporter induction BM012 Competitive inhibition of transporters BM017 CYP450 enzyme inhibition BM022 CYP450 enzyme induction BM024 Competitive inhibition of metabolic enzyme BM028 Competitive inhibition of renal tubular secretion BM066 Increased risk of hypomagnesemia BM109 Increased risk of other adverse reactions (Unspecific)
Relation Graph

Full list of drugs interacting with Omeprazole
Affected gastrointestinal absorption
	Altered gastric pH					Drug Num: 53
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1119		Nelfinavir	C32H45N3O4S	64143	Major		Inter Info	[4], [5], [6], [7]
D0008		Acalabrutinib	C26H23N7O2	71226662	Major		Inter Info	[8]
D0116		Atazanavir	C38H52N6O7	148192	Major		Inter Info	[9], [4], [10], [11], [12], [13], [7]
D0409		Dacomitinib	C24H25ClFN5O2	11511120	Major		Inter Info	[4], [39]
D0428		Dasatinib	C22H26ClN7O2S	3062316	Major		Inter Info	[40]
D0595		Erlotinib	C22H23N3O4	176870	Major		Inter Info	[9], [4], [41], [42]
D1124		Neratinib	C30H29ClN6O3	9915743	Major		Inter Info	[9], [45]
D1232		Pazopanib	C21H23N7O2S	10113978	Major		Inter Info	[4], [46], [47], [48], [49], [50]
D1258		Pexidartinib	C20H15ClF3N5	25151352	Major		Inter Info	[51]
D1404		Rilpivirine	C22H18N6	6451164	Major		Inter Info	[52]
D1459		Selpercatinib	C29H31N7O3	134436906	Major		Inter Info	[4], [53]
D1686		Velpatasvir	C49H54N8O8	67683363	Major		Inter Info	[4], [57]
D0074		Amphetamine	C9H13N	3007	Moderate		Inter Info	[58]
D0713		Gefitinib	C22H24ClFN4O3	123631	Moderate		Inter Info	[76]
D0799		Indinavir	C36H47N5O4	5362440	Moderate		Inter Info	[77]
D0934		Liothyronine	C15H12I3NO4	5920	Moderate		Inter Info	[9], [4], [78]
D0141		Bacampicillin	C21H27N3O7S	441397	Moderate		Inter Info	[101], [102]
D0195		Bosutinib	C26H29Cl2N5O3	5328940	Moderate		Inter Info	[106]
D0278		Cefditoren	C19H18N6O5S3	9870843	Moderate		Inter Info	[107]
D0288		Cefpodoxime	C15H17N5O6S2	6335986	Moderate		Inter Info	[101], [108], [109], [102]
D0297		Cefuroxime	C16H16N4O8S	5479529	Moderate		Inter Info	[101], [108], [109], [102]
D0302		Ceritinib	C28H36ClN5O3S	57379345	Moderate		Inter Info	[111]
D0439		Delavirdine	C22H28N6O3S	5625	Moderate		Inter Info	[115]
D0491		Digoxin	C41H64O14	2724385	Moderate		Inter Info	[116], [117], [118], [119], [69], [31], [70], [32], [71], [33], [60]
D0649		Ferrous fumarate	C4H2FeO4	6433164	Moderate		Inter Info	[136], [137], [69], [31], [70], [32], [71], [33], [138], [139]
D0650		Ferrous gluconate	C12H22FeO14	23616740	Moderate		Inter Info	[136], [137], [69], [31], [70], [32], [71], [33], [138], [139]
D0651		Ferrous sulfate anhydrous	FeO4S	24393	Moderate		Inter Info	[136], [31], [140]
D0692		Fosamprenavir	C25H36N3O9PS	131536	Moderate		Inter Info	[142]
D0847		Iron	Fe	23925	Moderate		Inter Info	[136], [31], [140]
D0849		Iron protein succinylate	NA	NA	Moderate		Inter Info	[136], [137], [69], [31], [70], [32], [71], [33], [138], [139]
D0894		Lapatinib	C29H26ClFN4O4S	208908	Moderate		Inter Info	[4], [152]
D0925		Levothyroxine	C15H11I4NO4	5819	Moderate		Inter Info	[9], [4], [78]
D0935		Liotrix	C30H21I7N2Na2O8	71371	Moderate		Inter Info	[9], [4], [78]
D1094		Mycophenolate mofetil	C23H31NO7	5281078	Moderate		Inter Info	[161], [162]
D1109		Naproxen	C14H14O3	156391	Moderate		Inter Info	[163]
D1315		Posaconazole	C37H42F2N8O4	468595	Moderate		Inter Info	[169], [170], [171], [172], [173], [174], [175], [176], [177], [178]
D1408		Riociguat	C20H19FN8O2	11304743	Moderate		Inter Info	[179]
D1577		Thyroid, porcine	NA	NA	Moderate		Inter Info	[9], [4], [78]
D0395		Cyanocobalamin	C63H88CoN14O14P	5311498	Minor		Inter Info	[189], [190], [191], [192], [193]
D0017		Acetylsalicylic acid	C9H8O4	2244	Minor		Inter Info	[200], [201], [202]
D0133		Axitinib	C22H18N4OS	6450551	Minor		Inter Info	[204]
D0331		Choline salicylate	C12H19NO4	54686350	Minor		Inter Info	[200], [201], [202]
D0341		Ciprofloxacin	C17H18FN3O3	2764	Minor		Inter Info	[207]
D0539		Duloxetine	C18H19NOS	60835	Minor		Inter Info	[211]
D0989		Mecobalamin	C63H91CoN13O14P	10898559	Minor		Inter Info	[190], [191], [193]
D1272		Phenyl salicylate	C13H10O3	8361	Minor		Inter Info	[200], [201], [202]
D1313		Ponatinib	C29H27F3N6O	24826799	Minor		Inter Info	[9], [217]
D1328		Prasugrel	C20H20FNO3S	6918456	Minor		Inter Info	[218], [36]
D1377		Raltegravir	C20H21FN6O5	54671008	Minor		Inter Info	[220]
D1439		Salicylic acid (sodium)	C7H6O3	338	Minor		Inter Info	[200], [201], [202]
D1442		Salsalate	C14H10O5	5161	Minor		Inter Info	[200], [201], [202]
D1681		Vandetanib	C22H24BrFN4O2	3081361	Minor		Inter Info	[9], [4], [46], [223]
D1701		Vismodegib	C19H14Cl2N2O3S	24776445	Minor		Inter Info	[9], [4], [224]
	Altered absorption (Unspecific)					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0861		Isosorbide dinitrate	C6H8N2O8	6883	Minor		Inter Info	[212]
D0862		Isosorbide mononitrate	C6H9NO6	27661	Minor		Inter Info	[212]
D1146		Nitroglycerin	C3H5N3O9	4510	Minor		Inter Info	[212]
Affected cellular transport
Affected intra/extra-hepatic metabolism
	CYP450 enzyme inhibition					Drug Num: 56
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0345		Citalopram	C20H21FN2O	2771	Major		Inter Info	[1], [2], [3]
D0336		Cilostazol	C20H27N5O2	2754	Major		Inter Info	[4], [14], [15], [16]
D0364		Clopidogrel	C16H16ClNO2S	60606	Major		Inter Info	[17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38]
D0481		Dicoumarol	C19H12O6	54676038	Moderate		Inter Info	[65], [66], [67]
D0667		Fluconazole	C13H12F2N6O	3365	Moderate		Inter Info	[4], [68], [69], [30], [70], [32], [71], [33], [72], [73]
D0687		Fluvoxamine	C15H21F3N2O2	5324346	Moderate		Inter Info	[74], [69], [70], [32], [71], [33], [75]
D0002		Abametapir (topical)	C12H12N2	15664	Moderate		Inter Info	[82]
D0045		Alprazolam	C17H13ClN4	2118	Moderate		Inter Info	[83], [84], [85], [86], [87]
D0087		Anisindione	C16H12O3	2197	Moderate		Inter Info	[89], [90], [69], [91], [30], [70], [65], [32], [33], [92], [93], [94], [66], [95], [67]
D0106		Armodafinil	C15H15NO2S	9690109	Moderate		Inter Info	[9], [97], [98], [99], [100]
D0300		Cenobamate	C10H10ClN5O2	11962412	Moderate		Inter Info	[110]
D0317		Chlordiazepoxide	C16H14ClN3O	2712	Moderate		Inter Info	[83], [84], [85], [86], [87]
D0356		Clobazam	C16H13ClN2O2	2789	Moderate		Inter Info	[112]
D0362		Clonazepam	C15H10ClN3O3	2802	Moderate		Inter Info	[83], [84], [85], [86], [87]
D0365		Clorazepic acid	C16H11ClN2O3	2809	Moderate		Inter Info	[83], [86], [87]
D0473		Diazepam	C16H13ClN2O	3016	Moderate		Inter Info	[83], [84], [85], [86], [87]
D0543		Duvelisib	C22H17ClN6O	50905713	Moderate		Inter Info	[120]
D0599		Escitalopram	C20H21FN2O	146570	Moderate		Inter Info	[123], [9], [4], [124], [125], [126], [127], [128], [129], [130], [131], [132], [133]
D0604		Estazolam	C16H11ClN4	3261	Moderate		Inter Info	[83], [84], [85], [86], [87]
D0638		Fedratinib	C27H36N6O3S	16722836	Moderate		Inter Info	[4], [134]
D0642		Fenofibrate	C20H21ClO4	3339	Moderate		Inter Info	[9], [4], [135]
D0665		Flibanserin	C20H21F3N4O	6918248	Moderate		Inter Info	[141]
D0679		Flurazepam	C21H23ClFN3O	3393	Moderate		Inter Info	[83], [84], [85], [86], [87]
D0697		Fosphenytoin	C16H15N2O6P	56339	Moderate		Inter Info	[116], [9], [4], [86], [143], [71]
D0699		Fostamatinib	C23H26FN6O9P	11671467	Moderate		Inter Info	[144]
D0748		Halazepam	C17H12ClF3N2O	31640	Moderate		Inter Info	[83], [84], [85], [86], [87]
D0867		Itraconazole	C35H38Cl2N8O4	55283	Moderate		Inter Info	[145], [146], [147], [148], [149], [150], [69], [70], [32], [71], [33], [151]
D0880		Ketoconazole	C26H28Cl2N4O4	456201	Moderate		Inter Info	[145], [146], [147], [148], [149], [150], [69], [70], [32], [71], [33], [151]
D0896		Larotrectinib	C21H22F2N6O2	46188928	Moderate		Inter Info	[9], [4], [153]
D0899		Lefamulin	C28H45NO5S	25185057	Moderate		Inter Info	[154], [155], [156]
D0946		Lonafarnib	C27H31Br2ClN4O2	148195	Moderate		Inter Info	[158]
D1081		Modafinil	C15H15NO2S	4236	Moderate		Inter Info	[9], [97], [98], [99], [100]
D1189		Osilodrostat	C13H10FN3	44139752	Moderate		Inter Info	[165]
D1198		Oxcarbazepine	C15H12N2O2	34312	Moderate		Inter Info	[9], [166]
D1299		Pirfenidone	C12H11NO	40632	Moderate		Inter Info	[4], [167], [168]
D1367		Quazepam	C17H11ClF4N2S	4999	Moderate		Inter Info	[83], [84], [85], [86], [87]
D1600		Tofacitinib	C16H20N6O	9926791	Moderate		Inter Info	[9], [4], [183]
D1632		Triazolam	C17H12Cl2N4	5556	Moderate		Inter Info	[83], [84], [85], [86], [87]
D1706		Voriconazole	C16H14F3N5O	71616	Moderate		Inter Info	[184], [185], [69], [30], [70], [32], [71], [33], [186], [187]
D1711		Warfarin	C19H16O4	54678486	Moderate		Inter Info	[89], [90], [69], [91], [30], [70], [65], [32], [33], [92], [93], [94], [66], [95], [67]
D1283		Phenytoin	C15H12N2O2	1775	Moderate		Inter Info	[116], [9], [4], [86], [143], [71]
D0193		Bortezomib	C19H25BN4O4	387447	Minor		Inter Info	[188]
D0727		Glimepiride	C24H34N4O5S	3476	Minor		Inter Info	[194], [70], [71], [195]
D0013		Acetohexamide	C15H20N2O4S	1989	Minor		Inter Info	[194], [70], [71], [195]
D0053		Ambrisentan	C22H22N2O4	6918493	Minor		Inter Info	[203]
D0208		Brivaracetam	C11H20N2O2	9837243	Minor		Inter Info	[4], [205]
D0248		Cannabidiol	C21H30O2	644019	Minor		Inter Info	[4], [206]
D0325		Chlorpropamide	C10H13ClN2O3S	2727	Minor		Inter Info	[194], [70], [71], [195]
D0349		Clarithromycin	C38H69NO13	84029	Minor		Inter Info	[208], [209], [210]
D0728		Glipizide	C21H27N5O4S	3478	Minor		Inter Info	[194], [70], [71], [195]
D0730		Glyburide	C23H28ClN3O5S	3488	Minor		Inter Info	[194], [70], [71], [195]
D1265		Phenobarbital	C12H12N2O3	4763	Minor		Inter Info	[216]
D1372		Quinine	C20H24N2O2	3034034	Minor		Inter Info	[219]
D1601		Tolazamide	C14H21N3O3S	5503	Minor		Inter Info	[194], [70], [71], [195]
D1603		Tolbutamide	C12H18N2O3S	5505	Minor		Inter Info	[194], [70], [71], [195]
D1674		Valdecoxib	C16H14N2O3S	119607	Minor		Inter Info	[222]
	CYP450 enzyme induction					Drug Num: 16
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0084		Anagrelide	C10H7Cl2N3O	135409400	Moderate		Inter Info	[9], [4], [59]
D0095		Apalutamide	C21H15F4N5O2S	24872560	Moderate		Inter Info	[4], [96]
D0157		Bendamustine	C16H21Cl2N3O2	65628	Moderate		Inter Info	[103]
D0182		Binimetinib	C17H15BrF2N4O3	10288191	Moderate		Inter Info	[9], [4], [104], [105]
D0370		Clozapine	C18H19ClN4	135398737	Moderate		Inter Info	[113], [114]
D0578		Enzalutamide	C21H16F4N4O2S	15951529	Moderate		Inter Info	[121], [9], [4], [122]
D0906		Letermovir	C29H28F4N4O4	45138674	Moderate		Inter Info	[157]
D0958		Lumacaftor	C24H18F2N2O5	16678941	Moderate		Inter Info	[159], [4], [160]
D1400		Rifampicin	C43H58N4O12	135398735	Moderate		Inter Info	[9], [70], [140]
D1493		Somapacitan	C54H95N13O20S2	129894493	Moderate		Inter Info	[9], [4], [180]
D1502		St. John's Wort	NA	NA	Moderate		Inter Info	[9], [70], [71]
D1536		Tasimelteon	C15H19NO2	10220503	Moderate		Inter Info	[181]
D1592		Tipranavir	C31H33F3N2O5S	54682461	Moderate		Inter Info	[123], [4], [182]
D0927		Lidocaine	C14H22N2O	3676	Minor		Inter Info	[196], [197], [198], [199]
D0916		Levobupivacaine	C18H28N2O	92253	Minor		Inter Info	[213]
D1405		Riluzole	C8H5F3N2OS	5070	Minor		Inter Info	[221]
	Competitive inhibition of metabolic enzyme					Drug Num: 4
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1526		Tacrolimus	C44H69NO12	445643	Major		Inter Info	[54], [55], [56]
D0956		Lovastatin	C24H36O5	53232	Moderate		Inter Info	[79], [80], [81]
D0120		Atorvastatin	C33H35FN2O5	60823	Moderate		Inter Info	[79], [80], [81]
D1473		Simvastatin	C25H38O5	54454	Moderate		Inter Info	[79], [80], [81]
Affected excretion pathways
	Competitive inhibition of renal tubular secretion					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1025		Methotrexate	C20H22N8O5	126941	Major		Inter Info	[9], [43], [44]
Pharmacodynamic additive effects
	Increased risk of hypomagnesemia					Drug Num: 37
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0252		Capreomycin	C50H88N28O15	3000502	Moderate		Inter Info	[60]
D0306		Cetuximab	NA	NA	Moderate		Inter Info	[60]
D0326		Chlorthalidone	C14H11ClN2O4S	2732	Moderate		Inter Info	[60]
D0402		Cyclosporine	C62H111N11O12	5284373	Moderate		Inter Info	[61], [62], [63], [64], [60]
D0056		Amikacin	C22H43N5O13	37768	Moderate		Inter Info	[60]
D0057		Amikacin (liposome)	C22H43N5O13	37768	Moderate		Inter Info	[70], [88], [60]
D0075		Amphotericin B	C47H73NO17	5280965	Moderate		Inter Info	[60]
D0076		Amphotericin B (cholesteryl sulfate)	C47H73NO17	5280965	Moderate		Inter Info	[70], [88], [60]
D0077		Amphotericin B (lipid complex)	C47H73NO17	5280965	Moderate		Inter Info	[70], [88], [60]
D0078		Amphotericin B (liposomal)	C47H73NO17	5280965	Moderate		Inter Info	[70], [88], [60]
D0158		Bendroflumethiazide	C15H14F3N3O4S2	2315	Moderate		Inter Info	[60]
D0217		Bumetanide	C17H20N2O5S	2471	Moderate		Inter Info	[60]
D0260		Carboplatin	C6H12N2O4Pt	426756	Moderate		Inter Info	[60]
D0321		Chlorothiazide	C7H6ClN3O4S2	2720	Moderate		Inter Info	[60]
D0344		Cisplatin	Cl2H6N2Pt	5702198	Moderate		Inter Info	[60]
D0694		Foscarnet	CH3O5P	3415	Moderate		Inter Info	[60]
D0704		Furosemide	C12H11ClN2O5S	3440	Moderate		Inter Info	[60]
D0718		Gentamicin	C21H43N5O7	3467	Moderate		Inter Info	[60]
D0771		Hydrochlorothiazide	C7H8ClN3O4S2	3639	Moderate		Inter Info	[60]
D0775		Hydroflumethiazide	C8H8F3N3O4S2	3647	Moderate		Inter Info	[60]
D0798		Indapamide	C16H16ClN3O3S	3702	Moderate		Inter Info	[60]
D0876		Kanamycin	C18H36N4O11	6032	Moderate		Inter Info	[60]
D1048		Metolazone	C16H16ClN3O3S	4170	Moderate		Inter Info	[60]
D1120		Neomycin	C23H46N6O13	8378	Moderate		Inter Info	[60]
D1126		Netilmicin	C21H41N5O7	441306	Moderate		Inter Info	[60]
D1136		Nilotinib	C28H22F3N7O	644241	Moderate		Inter Info	[164]
D1220		Panitumumab	NA	NA	Moderate		Inter Info	[60]
D1228		Paromomycin	C23H45N5O14	165580	Moderate		Inter Info	[60]
D1231		Patiromer	NA	NA	Moderate		Inter Info	[60]
D1246		Pentamidine	C19H24N4O2	4735	Moderate		Inter Info	[60]
D1304		Plazomicin	C25H48N6O10	42613186	Moderate		Inter Info	[60]
D1311		Polythiazide	C11H13ClF3N3O4S3	4870	Moderate		Inter Info	[60]
D1507		Streptomycin	C21H39N7O12	19649	Moderate		Inter Info	[60]
D1597		Tobramycin	C18H37N5O9	36294	Moderate		Inter Info	[60]
D1605		Tolevamer	C11H16O3S	58817179	Moderate		Inter Info	[70], [88], [60]
D1633		Trichlormethiazide	C8H8Cl3N3O4S2	5560	Moderate		Inter Info	[60]
D1611		Torasemide	C16H20N4O3S	41781	Moderate		Inter Info	[70], [88], [60]
	Increased risk of other adverse reactions (Unspecific)					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0929		Linaclotide	C59H79N15O21S6	16158208	Minor		Inter Info	[214], [215]

References
1	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide).".
2	Priskorn M, Larsen F, Segonzac A, Moulin M "Pharmacokinetic interaction study of citalopram and cimetidine in healhy subjects." Eur J Clin Pharmacol 52 (1997): 241-2. [PMID: 9218934]
3	Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
4	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
5	Fang AF, Damle BD, Labadie RR, Crownover PH, Hewlett D, Glue PW "Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects." Pharmacotherapy 28 (2008): 42-50. [PMID: 18154473]
6	Product Information. Viracept (nelfinavir). Agouron Pharma Inc, La Jolla, CA.
7	Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P "Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study." Aids 14 (2000): 1333-9. [PMID: 10930147]
8	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
9	Cerner Multum, Inc. "Australian Product Information.".
10	Drug interactions. Atazanavir and acid-reducing agents. TreatmentUpdate 18 (2006): 4. [PMID: 17209238]
11	Product Information. Evotaz (atazanavir-cobicistat). Bristol-Myers Squibb, Princeton, NJ.
12	Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
13	Ray JE, Marriott D, Bloch MT, McLachlan AJ "Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic." Br J Clin Pharmacol 60 (2005): 291-9. [PMID: 16120068]
14	Product Information. Pletal (cilostazol). Otsuka American Pharmaceuticals, Rockville, MD.
15	Suri A, Bramer SL "Effect of omeprazole on the metabolism of cilostazol." Clin Pharmacokinet 37 (1999): 53-9. [PMID: 10702887]
16	Suri A, Forbes WP, Bramer SL "Effects of CYP3A inhibition on the metabolism of cilostazol." Clin Pharmacokinet 37 (1999): 61-8. [PMID: 10702888]
17	Collet JP, Hulot JS, Pena A, et al. "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study." Lancet 373 (2009): 309-17. [PMID: 19108880]
18	de Aquino Lima JP, Brophy JM "The potential interaction between clopidogrel and proton pump inhibitors: a systematic review." BMC Med 8 (2010): 81. [PMID: 21134261]
19	Freedman JE, Hylek EM "Clopidogrel, genetics, and drug responsiveness." N Engl J Med 360 (2009): 411-3. [PMID: 19164193]
20	Frere C, Cuisset T, Morange PE, et al. "Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome." Am J Cardiol 101 (2008): 1088-1093. [PMID: 18394438]
21	Gilard M, Arnaud B, Cornily JC, et al "Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study." J Am Coll Cardiol 51 (2008): 256-60. [PMID: 18206732]
22	Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J "Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin." J Thromb Haemost 4 (2006): 2508-9. [PMID: 16898956]
23	Hulot JS, Bura A, Villard E, et al. "Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects." Blood (2006):. [PMID: 16772608]
24	Juurlink DN, Gomes T, Ko DT, et al "A population-based study of the drug interaction between proton pump inhibitors and clopidogrel." CMAJ 180 (2009): 713-8. [PMID: 19176635]
25	Lau WC, Gurbel PA "The drug-drug interaction between proton pump inhibitors and clopidogrel." CMAJ 180 (2009): 699-700. [PMID: 19332744]
26	Li XQ, Andersson TB, Ahlstrom M, Weidolf L "Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities." Drug Metab Dispos 32 (2004): 821-7. [PMID: 15258107]
27	Mega JL, Close SL, Wiviott SD, et al. "Cytochrome p-450 polymorphisms and response to clopidogrel." N Engl J Med 360 (2009): 354-62. [PMID: 19106084]
28	Moayyedi P, Sadowski DC "Proton pump inhibitors and clopidogrel -- hazardous drug interaction or hazardous interpretation of data?" Can J Gastroenterol 23 (2009): 251-2. [PMID: 19373416]
29	Pezalla E, Day D, Pulliadath I "Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors." J Am Coll Cardiol 52 (2008): 1038-9. [PMID: 18786491]
30	Product Information. Dexilant (dexlansoprazole). Takeda Pharmaceuticals America, Lincolnshire, IL.
31	Product Information. Kapidex (dexlansoprazole). Takeda Pharmaceuticals America, Lincolnshire, IL.
32	Product Information. Prevacid (lansoprazole). TAP Pharmaceuticals Inc, Deerfield, IL.
33	Product Information. Protonix (pantoprazole) Wyeth-Ayerst Laboratories, Philadelphia, PA.
34	Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B "Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel." Am Heart J 157 (2009): 148.e1-5. [PMID: 19081411]
35	Simon T, Verstuyft C, Mary-Krause M, et al "Genetic determinants of response to clopidogrel and cardiovascular events." N Engl J Med 360 (2009): 363-75. [PMID: 19106083]
36	Small DS, Farid NA, Payne CD, et al. "Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel." J Clin Pharmacol 48 (2008): 475-84. [PMID: 18303127]
37	Varenhorst C, Janes S, Erlinge D, et al "Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease." Eur Heart J 30 (2009): 1744-52. [PMID: 19429918]
38	EMA. European Medicines Agency "Interaction between clopidogrel and proton-pump inhibitors.".
39	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
40	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
41	Duong S, Leung M "Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents." J Oncol Pharm Pract 17 (2011): 448-52. [PMID: 20716581]
42	Product Information. Tarceva (erlotinib). Genentech, South San Francisco, CA.
43	Breedveld P, Zelcer N, Pluim D, et.al "Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions." Cancer Res 64 (2004): 5804-11.[PMID: 15313923]
44	Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J "Potential interaction between methotrexate and omeprazole/." Ann Pharmacother 34 (2000): 1024-7.[PMID: 10981249]
45	Product Information. Nerlynx (neratinib). Puma Biotechnology, Inc., Los Angeles, CA.
46	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
47	Product Information. Votrient (pazopanib). GlaxoSmithKline, Research Triangle Park, NC.
48	Tan AR, Gibbon DG, Stein MN, et al. "Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors." Cancer Chemother Pharmacol 71 (2013): 1635-43. [PMID: 23636448]
49	van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG "Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective." Lancet Oncol 15 (2014): e315-e326. [PMID: 24988935]
50	Yu G, Zheng QS, Wang DX, Zhou HH, Li GF "Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye." Lancet Oncol 15 (2014): e469-70. [PMID: 25281461]
51	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
52	Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
53	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
54	Itagaki F, Homma M, Yuzawa K, et al "Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations." J Pharm Pharmacol 56 (2004): 1055-9. [PMID: 15285851]
55	Lorf T, Ramadori G, Ringe B, Schworer H "The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients." Eur J Clin Pharmacol 56 (2000): 439-40. [PMID: 11009056]
56	Miura M, Inoue K, Kagaya H, et al. "Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients." Biopharm Drug Dispos 28 (2007): 167-75. [PMID: 17377957]
57	Product Information. Epclusa (sofosbuvir-velpatasvir). Gilead Sciences, Foster City, CA.
58	Product Information. Adderall XR (amphetamine-dextroamphetamine). Shire Richwood Pharmaceutical Company Inc, Florence, KY.
59	Product Information. Agrylin (anagrelide). Roberts Pharmaceutical Corporation, Eatontown, NJ.
60	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
61	Arranz R, Yanez E, Franceschi JL, Fernandez-Ranada JM "More about omeparazole-cyclosporine interaction." Am J Gastroenterol 88 (1993): 154. [PMID: 8420264]
62	Blohme I, Idstrom JP, Andersson T "A study of the interaction between omeprazole and cyclosporine in renal transplant patients." Br J Clin Pharmacol 35 (1993): 156-60. [PMID: 8443034]
63	Castellote E, Bonet J, Lauzurica R, Pastor C, Cofan F, Caralps A "Does interaction between omeprazole and cyclosporin exist?" Nephron 65 (1993): 478. [PMID: 8290007]
64	Schouler L, Dumas F, Couzigou P, et al "Omeprazole-cyclosporin interaction." Am J Gastroenterol 86 (1991): 1097. [PMID: 1858755]
65	Product Information. Omeprazole (omeprazole). Mylan Pharmaceuticals Inc, Morgantown, WV.
66	Sutfin T, Blamer K, Bostrom H, Eriksson S, Hoglund P, Paulsen O "Stereoselective interaction of omeprazole with warfarin in healthy men." Ther Drug Monit 11 (1989): 176-84. [PMID: 2718223]
67	Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83. [PMID: 7944078]
68	Niwa T, Shiraga T, Takagi A "Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, CYP3A4 activities in human liver microsomes." Biol Pharm Bull 28 (2005): 1805-8. [PMID: 16141567]
69	Product Information. Aciphex (rabeprazole) Janssen Pharmaceuticals, Titusville, NJ.
70	Product Information. Nexium (esomeprazole) Astra-Zeneca Pharmaceuticals, Wilmington, DE.
71	Product Information. Prilosec (omeprazole). Merck & Co, Inc, West Point, PA.
72	Zimmermann T, Yeates RA, Riedel KD, Lach P, Laufen H "The influence of gastric ph on the pharmacokinetics of fluconazole: the effect of omeprazole." Int J Clin Pharmacol Ther 32 (1994): 491-6. [PMID: 7820333]
73	Lu C, Berg C, Prakash SR, Lee FW, Balani SK "Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole." Drug Metab Dispos 36 (2008): 1261-6. [PMID: 18381488]
74	Christensen M, Tybring G, Mihara K, et al. "Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)." Clin Pharmacol Ther 71 (2002): 141-52. [PMID: 11907488]
75	Yasui-Furukori N, Takahata T, Nakagami T, et al. "Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes." Br J Clin Pharmacol 57 (2004): 487-94. [PMID: 15025747]
76	Product Information. Iressa (gefitinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
77	Burger DM, Hugen PWH, Kroon FP, Groeneveld P, Brinkman K, Foudraine NA, Sprenger H, Koopmans PP, Hekster YA "Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir." AIDS 12 (1998): 2080-2. [PMID: 9814882]
78	Product Information. Synthroid (levothyroxine). Abbott Pharmaceutical, Abbott Park, IL.
79	Bogman K, Peyer AK, Torok M, Kusters E, Drewe J "HMG-CoA reductase inhibitors and P-glycoprotein modulation." Br J Pharmacol 132 (2001): 1183-92. [PMID: 11250868]
80	Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF "Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein." Naunyn Schmiedebergs Arch Pharmacol 364 (2001): 551-7. [PMID: 11770010]
81	Sipe BE, Jones RJ, Bokhart GH "Rhabdomyolysis Causing AV Blockade Due to Possible Atorvastatin, Esomeprazole, and Clarithromycin Interaction." Ann Pharmacother 37 (2003): 808-11. [PMID: 12773066]
82	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
83	Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, Lundborg P "Effect of omeprazole and cimetidine on plasma diazepam levels." Eur J Clin Pharmacol 39 (1990): 51-4. [PMID: 2276389]
84	Andersson T, Cederberg C, Edvardsson G, et al "Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole." Clin Pharmacol Ther 47 (1990): 79-85. [PMID: 2104790]
85	Caraco Y, Tateishi T, Wood AJJ "Interethnic difference in omeprazole's inhibition of diazepam metabolism." Clin Pharmacol Ther 58 (1995): 62-72. [PMID: 7628184]
86	Gugler R, Jensen JC "Omeprazole inhibits oxidative drug metabolism: studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro." Gastroenterology 89 (1985): 1235-41. [PMID: 3932118]
87	Jacob RS, de Souza Santos LV, d'Auriol M, Lebron YAR, Moreira VR, Lange LC. Diazepam, metformin, omeprazole and simvastatin: a full discussion of individual and mixture acute toxicity.?Ecotoxicology. 2020;29(7):1062-1071. [PMID: 32588236]
88	Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67. [PMID: 19667002]
89	Ahmad S "Omeprazole-warfarin interaction." South Med J 84 (1991): 674-5. [PMID: 2035104]
90	Andersson T, HassanAlin M, Hasselgren G, Rohss K "Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole." Clin Pharmacokinet 40 (2001): 523-37. [PMID: 11510629]
91	Product Information. Coumadin (warfarin). DuPont Pharmaceuticals, Wilmington, DE.
92	Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW "Lack of pantoprazole drug interactions in man." Int J Clin Pharmacol Ther 32 (1994): 385-99. [PMID: 7981922]
93	Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW "Lack of pantoprazole drug interactions in man: an updated review." Int J Clin Pharmacol Ther 34 (1 suppl) (1996): s31-50. [PMID: 8793602]
94	Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW "Lack of pantoprazole drug interactions in man: an updated review." Int J Clin Pharmacol Ther 34 (1996): 243-62. [PMID: 8793611]
95	Unge P, Svedberg LE, Nordgren A, et al. "A study of the interaction of omeprazole and warfarin in anticoagulated patients." Br J Clin Pharmacol 34 (1992): 509-12. [PMID: 1493083]
96	Product Information. Erleada (apalutamide). Janssen Biotech, Inc., Horsham, PA, PA.
97	Dequardo JR "Modafinil-associated clozapine toxicity." Am J Psychiatry 159 (2002): 1243-1244. [PMID: 12091210]
98	Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
99	Product Information. Provigil (modafinil). Cephalon, Inc, West Chester, PA.
100	Robertson P, Decory HH, Madan A, Parkinson A "In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil." Drug Metab Dispos 28 (2000): 664-71. [PMID: 10820139]
101	Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
102	Sommers DK, van Wyk M, Moncrieff J, Schoeman HS "Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil." Br J Clin Pharmacol 18 (1984): 535-9. [PMID: 6091711]
103	Product Information. Treanda (bendamustine). Cephalon Inc, West Chester, PA.
104	Product Information. Mektovi (binimetinib). Array BioPharma Inc., Boulder, CO.
105	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
106	Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
107	Product Information. Spectracef (cefditoren). TAP Pharmaceuticals Inc, Deerfield, IL.
108	Hughes GS, Heald DL, Barker KB, et al. "The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil." Clin Pharmacol Ther 46 (1989): 674-85. [PMID: 2557183]
109	Saathoff N, Lode H, Neider K, et al "Pharmacokinetics of cefpodoxime and interactions with an antacid and an H2 receptor antagonist." Antimicrob Agents Chemother 36 (1992): 796-800. [PMID: 1354432]
110	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
111	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
112	Product Information. Onfi (clobazam). Lundbeck Inc, Deerfield, IL.
113	Frick A, Kopitz J, Bergemann N "Omeprazole reduces clozapine plasma concentrations. A case report." Pharmacopsychiatry 36 (2003): 121-3. [PMID: 12806570]
114	Mookhoek EJ, Loonen AJ "Retrospective evaluation of the effect of omeprazole on clozapine metabolism." Pharm World Sci 26 (2004): 180-2. [PMID: 15230368]
115	Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
116	Andersson T "Omeprazole drug interaction studies." Clin Pharmacokinet 21 (1991): 195-212. [PMID: 1764870]
117	Kiley CA, Cragin DJ, Roth BJ "Omeprazole-associated digoxin toxicity." South Med J 100 (2007): 400-2. [PMID: 17458401]
118	Le GH, Schaefer MG, Plowman BK, et al. "Assessment of potential digoxin-rabeprazole interaction after formulary conversion of proton-pump inhibitors." Am J Health Syst Pharm 60 (2003): 1343-5. [PMID: 12901036]
119	Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB, Jedema JN "Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose." Br J Clin Pharmacol 32 (1991): 569-72. [PMID: 1954072]
120	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
121	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
122	Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
123	Canadian Pharmacists Association.
124	Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
125	Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2. [PMID: 7476638]
126	Laird LK "Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder." Psychopharmacol Bull 32 (1996): 569-78. [PMID: 8993077]
127	Lane R, Baldwin D "Selective serotonin reuptake inhibitor--induced serotonin syndrome: review." J Clin Psychopharmacol 17 (1997): 208-21. [PMID: 9169967]
128	Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6. [PMID: 8909274]
129	Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763. [PMID: 9330840]
130	Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8. [PMID: 8257462]
131	Nijhawan PK, Katz G, Winter S "Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission." Crit Care Med 24 (1996): 1086-9. [PMID: 8681579]
132	Product Information. Lexapro (escitalopram). Forest Pharmaceuticals, St. Louis, MO.
133	Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13. [PMID: 2035713]
134	Product Information. Inrebic (fedratinib). Celgene Corporation, Summit, NJ.
135	Product Information. Antara (fenofibrate). Lupin Pharmaceuticals Inc, Baltimore, MD.
136	Hutchison C, Geissler CA, Powell JJ, Bomford A "Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis." Gut 56 (2007): 1291-5. [PMID: 17344278]
137	Nand S, Tanvetyanon T "Proton pump inhibitors and iron deficiency: is the connection real?" South Med J 97 (2004): 799. [PMID: 15455957]
138	Sharma VR, Brannon MA, Carloss EA "Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia." South Med J 97 (2004): 887-9. [PMID: 15455980]
139	Stewart CA, Termanini B, Sutliff VE, et al "Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy." Aliment Pharmacol Ther 12 (1998): 83-98. [PMID: 9692706]
140	Product Information. Prilosec (omeprazole). Merck &amp Co, Inc, West Point, PA.
141	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
142	Product Information. Lexiva (fosamprenavir). GlaxoSmithKline, Research Triangle Park, NC.
143	Prichard PJ, Walt RP, Kitchingman GK, et al. "Oral phenytoin pharmacokinetics during omeprazole therapy." Br J Clin Pharmacol 24 (1987): 543-5. [PMID: 3689634]
144	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
145	Bottiger Y, Tybring G, Gotharson E, Bertilsson L "Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin." Clin Pharmacol Ther 62 (1997): 384-91. [PMID: 9357389]
146	Carlson JA, Mann HJ, Canafax DM "Effect of pH on disintegration and dissolution of ketoconazole tablets." Am J Hosp Pharm 40 (1983): 1334-6. [PMID: 6310994]
147	Chin TWF, Loeb M, Fong IW "Effects of an acidic beverage (coca-cola) on absorption of ketoconazole." Antimicrob Agents Chemother 39 (1995): 1671-5. [PMID: 7486898]
148	Jaruratanasirikul S, Sriwiriyajan S "Effect of omeprazole on the pharmacokinetics of itraconazole." Eur J Clin Pharmacol 54 (1998): 159-61. [PMID: 9626921]
149	Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32. [PMID: 10730911]
150	Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ "Effects of ranitidine and sucralfate on ketoconazole bioavailability." Antimicrob Agents Chemother 35 (1991): 1765-71. [PMID: 1952845]
151	Van der Meer JW, Keuning JJ "The influence of gastric acidity on the bio-availability of ketoconazole." J Antimicrob Chemother 6 (1980): 552-4. [PMID: 6253434]
152	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
153	Product Information. Vitrakvi (larotrectinib). Bayer Pharmaceutical Inc, West Haven, CT.
154	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
155	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
156	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
157	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
158	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
159	Cerner Multum, Inc. "Canadian Product Information.".
160	Product Information. Orkambi (ivacaftor-lumacaftor). Vertex Pharmaceuticals, Cambridge, MA.
161	Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
162	Product Information. Myfortic (mycophenolic acid). Novartis Pharmaceuticals, East Hanover, NJ.
163	Product Information. Naprosyn (naproxen). Syntex Laboratories Inc, Palo Alto, CA.
164	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
165	Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
166	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
167	Product Information. Esbriet (pirfenidone). Intermune Inc, Brisbane, CA.
168	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
169	Alffenaar JW, van Assen S, van der Werf TS, Kosterink JG, Uges DR "Omeprazole significantly reduces posaconazole serum trough level." Clin Infect Dis 48 (2009): 839. [PMID: 19220151]
170	Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ "Multicenter study of posaconazole therapeutic drug monitoring: exposure-response and factors affecting concentration." Antimicrob Agents Chemother 56 (2012): 5503-10. [PMID: 22890761]
171	Krishna G, Abutarif M, Xuan F, Martinho M, Angulo D, Cornely OA "Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome." Pharmacotherapy 28 (2008): 1223-32. [PMID: 18823218]
172	Krishna G, Moton A, Ma L, Medlock MM, McLeod J "The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers." Antimicrob Agents Chemother 53 (2009): 958-66. [PMID: 19075045]
173	Neubauer WC, Engelhardt M, Konig A, et al. "Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method." Antimicrob Agents Chemother 54 (2010): 4029-32. [PMID: 20547790]
174	Product Information. Noxafil (posaconazole). Schering-Plough Corporation, Kenilworth, NJ.
175	Shields RK, Clancy CJ, Vadnerkar A, et al "Posaconzaole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy." Antimicrob Agents Chemother 55 (2011): 1308-11. [PMID: 21189337]
176	Vaes M, Hites M, Cotton F, et al. "Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplasic syndrome." Antimicrob Agents Chemother 56 (2012): 6298-303. [PMID: 23027198]
177	Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P "Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole: Monitoring of Intraluminal and Plasma Drug Concentrations." Clin Pharmacokinet 50 (2011): 725-34. [PMID: 21973269]
178	Krishna G, Moton A, Ma L, Malavade D, Medlock M, McLeod J "Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastro-intestinal motility on absorption and pharmacokinetics of the antifungal posaconazole." 18th European Congress of Clinical Microbiology and Infectious Diseases April (2008): 20.
179	Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
180	Product Information. Zorbtive (somatropin). Serono Laboratories Inc, Rockland, MA.
181	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
182	Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
183	Product Information. Xeljanz (tofacitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
184	Eiden C, Peyriere H, Tichit R, et al. "Inherited long QT syndrome revealed by antifungals drug-drug interaction." J Clin Pharm Ther 32 (2007): 321-4. [PMID: 17489884]
185	Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O "Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes." Clin Infect Dis 46 (2008): 201-11. [PMID: 18171251]
186	Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
187	Wood N, Tan K, Purkins L, et al. "Effect of omeprazole on the steady-state pharmacokinetics of voriconazole." Br J Clin Pharmacol 56 Suppl 1 (2003): 56-61. [PMID: 14616415]
188	Product Information. Velcade (bortezomib). Millennium Pharmaceuticals Inc, Cambridge, MA.
189	Bradford GS, Taylor CT "Omeprazole and vitamin B-12 deficiency." Ann Pharmacother 33 (1999): 641-3. [PMID: 10369631]
190	Dutta SK "Vitamin b-12 malabsorption and omeprazole therapy." J Am Coll Nutr 13 (1994): 544-5. [PMID: 7706583]
191	Lavy NW "Omeprazole and vitamin B12." Ann Intern Med 121 (1994): 74. [PMID: 8198354]
192	Marcuard SP, Albernaz L, Khazanie PG "Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin-b12)." Ann Intern Med 120 (1994): 211-5. [PMID: 8273984]
193	Salom IL, Silvis SE, Doscherholmen A "Effect of cimetidine on the absorption of vitamin B12." Scand J Gastroenterol 17 (1982): 129-31. [PMID: 7134827]
194	Humphries TJ "Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole." Dig Dis Sci 36 (1991): 1665-9. [PMID: 1748033]
195	Toon S, Holt BL, Mullins FGP, Khan A "Effects of cimetidine, ranitidine and omeprazole on tolbutamide pharmacokinetics." J Pharm Pharmacol 47 (1995): 85-8.
196	Heinonen J, Takki S, Jarho L "Plasma lidocaine levels in patients treated with potential inducers of microsomal enzymes." Acta Anaesthesiol Scand 14 (1970): 89-95. [PMID: 5428253]
197	Perucca E, Richens A "Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients." Br J Clin Pharmacol 8 (1979): 21-31. [PMID: 552293]
198	Perucca E, Ruprah M, Richens A, Park BK, Betteridge DJ, Hedges AM "Effect of low-dose phenobarbitone on five indirect indices of hepatic microsomal enzyme induction and plasma lipoproteins in normal subjects." Br J Clin Pharmacol 12 (1981): 592-6. [PMID: 6117310]
199	Reichel C, Skodra T, Nacke A, Spengler U, Sauerbruch T "The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans." Br J Clin Pharmacol 46 (1998): 535-9. [PMID: 9862241]
200	Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325?mg + immediate-release omeprazole 40?mg) or enteric-coated aspirin 325?mg + enteric-coated omeprazole 40?mg - a randomised, phase 1, crossover study.?Aliment Pharmacol Ther. 2013;38(1):62-71. [PMID: 23692061]
201	Inarrea P, Esteva F, Cornudella R, Lanas A "Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man." Scand J Gastroenterol 35 (2000): 242-6. [PMID: 10766315]
202	Nefesoglu FZ, Ayanoglu-Dulger G, Ulusoy NB, Imeryuz N "Interaction of omeprazole with enteric-coated salicylate tablets." Int J Clin Pharmacol Ther 36 (1998): 549-53. [PMID: 9799060]
203	Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
204	Product Information. Inlyta (axitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
205	Product Information. Briviact (brivaracetam). UCB Pharma Inc, Smyrna, GA.
206	Product Information. Epidiolex (cannabidiol). Greenwich Biosciences Inc, Carlsbad, CA.
207	Product Information. Cipro XR (ciprofloxacin). Bayer Pharmaceutical Inc, West Haven, CT.
208	Gustavson LE, Kaiser JF, Edmonds AL, Locke CS, DeBartolo ML, Schneck DW "Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state." Antimicrob Agents Chemother 39 (1995): 2078-83. [PMID: 8540719]
209	Zhou Q, Yamamoto I, Fukuda T, Ohno M, Sumida A, Azuma J "CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin." Eur J Clin Pharmacol 55 (1999): 43-7. [PMID: 10206083]
210	Furuta T, Ohashi K, Kobayashi K, Iida I, Yoshida H, Shirai N, Takashima M, Kosuge K, Hanai H, Chiba K, Ishizaki T, Kaneko E "Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans." Clin Pharmacol Ther 66 (1999): 265-74. [PMID: 10511062]
211	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
212	Kajinami K, Mabuchi H "Omeprazole and diminished antianginal drug delivery." Ann Intern Med 121 (1994): 385-6. [PMID: 8042836]
213	Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
214	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
215	Product Information. Linzess (linaclotide). Forest Pharmaceuticals, St. Louis, MO.
216	Klotz U "The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications." Clin Pharmacokinet 46 (2007): 271-9. [PMID: 17375979]
217	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
218	Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
219	Zhao XJ, Ishizaki T "A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (K-i) and type of inhibition." Eur J Drug Metab Pharm 24 (1999): 272-8. [PMID: 10716067]
220	Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
221	Product Information. Rilutek (riluzole). Rhone-Poulenc Rorer, Collegeville, PA.
222	Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ.
223	Product Information. Vandetanib (vandetanib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
224	Product Information. Erivedge (vismodegib). Genentech, South San Francisco, CA.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence